Quantcast

Latest Biologic Stories

2014-02-04 08:33:11

ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York. A live webcast of Synthetic Biologics' presentation may be accessed by...

2014-02-03 12:27:27

LONDON, Feb. 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Biologics and Biosimilars World Markets Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics...

2014-02-03 00:21:09

Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz(TM), is a biosimilar to Roche's...

2014-01-31 23:24:50

The Biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (PRWEB) January 31, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major...

2014-01-30 23:23:35

Fundamentals of Canadian Regulatory Affairs, Fourth Edition reflects the changes in technology in the three years since the previous edition was published in 2011, and examines their impact on regulations. Rockville, MD, USA (PRWEB) January 30, 2014 The Regulatory Affairs Professionals Society (RAPS) has updated its essential reference text, Fundamentals of Canadian Regulatory Affairs, the only book of its kind extensively covering the regulation of healthcare products marketed in Canada....

2014-01-29 23:35:14

Gallus BioPharmaceuticals, a premier pure-play biologics contract manufacturing organization, has completed a second expansion of its Process Development facility at its headquarters in St. Louis, Missouri. This expansion provides additional laboratory space and state-of-the-art instrumentation to support Gallus’ growth and commitment to leading pharma and biotech clients in the development of new biotherapeutics. St. Louis, Missouri (PRWEB) January 29, 2014 Gallus BioPharmaceuticals,...

2014-01-28 08:29:41

AT-005 Marks Aratana's First Commercial Opportunity in T-cell Canine Lymphoma KANSAS CITY, Kan., Jan. 28, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that the United States Department of Agriculture (USDA) has granted conditional approval for AT-005, Aratana's...

2014-01-27 08:27:07

-- Joseph Sliman, M.D., M.P.H., Joins Team as Senior Vice President, Clinical & Regulatory Affairs -- ROCKVILLE, Md., Jan. 27, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Joseph Sliman, M.D., M.P.H., joined the team and will assume the role of Senior Vice President, Clinical & Regulatory Affairs, previously held by Carol...

2014-01-22 12:26:41

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class InnovationFrontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation SummaryGBI Research has released a new pharmaceutical report, "Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation". This highly competitive market...

2014-01-22 10:29:51

Levels of depression and anxiety in people with severe rheumatoid arthritis are higher than previously reported, according to new research. As a result of their findings, a multi-center team led by researchers at the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester, say that patients with severe active disease, who are waiting to go onto a biological therapy, should be routinely screened for depression by their doctors. The team, led by Professor...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related